4.6 Article

Angiopoietin-2-Driven Vascular Remodeling in Airway Inflammation

期刊

AMERICAN JOURNAL OF PATHOLOGY
卷 177, 期 6, 页码 3233-3244

出版社

ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2010.100059

关键词

-

资金

  1. NIH [HL 024136, HL 059157, HL 096511]
  2. National Heart Lung and Blood Institute
  3. Belgian American Educational Foundation
  4. Centre Anticancereux (University of Liege Belgium)

向作者/读者索取更多资源

Vascular remodeling is a feature of chronic inflammation during which capillaries transform into venules that expand the region of the vasculature in which leakage and leukocyte emigration both occur Recently we found that angiopoietin/Tie2 receptor signaling drives the transformation of capillaries into venules at an early stage of the sustained inflammatory response m the airways of mice infected with Mycoplasma put moms However the precise contributions of both angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) are not clear In this study we sought to determine the contribution of Ang2 to this vascular remodeling Ang2 mRNA expression levels increased and phosphorylated Tie2 immunoreactivity m mucosal blood vessels decreased indicative of diminished receptor signaling after infection Selective inhibition of Ang2 throughout the infection by administration of either of two distinct function blocking antibodies reduced the suppression of Tie2 phosphorylation and decreased the remodeling of mucosal capillaries into venules the amount of leukocyte influx and disease severity These findings are consistent with Ang2 acting as an antagonist of Tie2 receptors and the reduction of Tie2 phosphorylation in endothelial cells rendering the vasculature more responsive to cytokines that promote both vascular remodeling and the consequences of inflammation after M pul moms infection By blocking such changes Ang2 in hibitors may prove beneficial in the treatment of sus tamed inflammation in which vascular remodeling leakage and leukocyte influx contribute to its pathophysiology (Am J Pathol 2010 1773233-3244, DOI 10 2353/ajpath 2010 100059)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function

Courtney M. Williams, Jessica Harper Calderon, E. Hock, Yasalp Jimenez, Kevin Barringer, Marisa Carbonaro, Maria del Pilar Molina-Portela, Gavin Thurston, Zhe Li, Christopher Daly

Summary: Human Fibroblast Growth Factor 19 (FGF19) and mouse ortholog Fgf15 exhibit similar roles in liver regeneration and metabolism through the activation of Fgfr4/b-klotho (Klb). FGF19 has stronger effects on glucose and fatty acid metabolism compared to Fgf15, and only FGF19 can induce hepatocellular carcinoma (HCC). However, inhibiting FGF19/FGFR4 signaling in HCC patients may lead to toxicity from elevated bile acid levels.

FASEB JOURNAL (2021)

Article Hematology

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

David J. DiLillo, Kara Olson, Katja Mohrs, Thomas Craig Meagher, Kevin Bray, Olga Sineshchekova, Thomas Startz, Jessica Kuhnert, Marc W. Retter, Stephen Godin, Prachi Sharma, Frank Delfino, John Lin, Eric Smith, Gavin Thurston, Jessica R. Kirshner

Summary: CD3-engaging bispecific antibodies and CAR T cells are effective therapeutic approaches for treating tumors by redirecting T cells. A fully human bispecific antibody (REGN5458) was introduced, showing potent antitumor activities against MM. In comparison to anti-BCMA CAR T cells, this bsAb demonstrated rapid clearance of MM tumors in animal models, suggesting differences in therapeutic mechanisms.

BLOOD ADVANCES (2021)

Article Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Alexander J. Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset-Seguin, Anne Lynn S. Chang, Stephane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Vladimir Jankovic, Nathalie Fiaschi, Emmanuel Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy Bowler, Matthew G. Fury

Summary: In patients resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 showed higher efficacy compared to ipilimumab monotherapy, with a higher objective response rate, longer progression-free survival, and longer overall survival, while maintaining a similar rate of grade 3-5 toxicity.

LANCET ONCOLOGY (2021)

Article Multidisciplinary Sciences

A framework for highly multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity

Wen Zhang, Peter G. Hawkins, Jing He, Namita T. Gupta, Jinrui Liu, Gabrielle Choonoo, Se W. Jeong, Calvin R. Chen, Ankur Dhanik, Myles Dillon, Raquel Deering, Lynn E. Macdonald, Gavin Thurston, Gurinder S. Atwal

Summary: This study introduces a computational framework with a novel method ICON for identifying reliable TCR-pMHC interactions and a neural network-based classifier TCRAI for predicting TCR-antigen specificity, which outperforms other state-of-the-art methods. The combination of ICON and TCRAI enables the discovery of novel subgroups of TCRs binding to a given pMHC via different mechanisms, facilitating the identification and understanding of TCR-antigen-specific interactions for basic immunological research and clinical immune monitoring.

SCIENCE ADVANCES (2021)

Article Oncology

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Retter, Rabih Slim, Tara M. Young, William C. Olson, Gavin Thurston, Christopher Daly

Summary: Lung cancers with MET genetic alterations respond well to MET-selective inhibitors, but a small percentage of patients benefit and acquired resistance is a limitation. An ADC targeting MET shows potential for effective treatment of MET-overexpressing tumors that do not respond to current therapies. Preclinical studies demonstrate that METxMET-M114 induces substantial and durable tumor regression, indicating promise as a candidate for MET-overexpressing tumor treatment.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Multidisciplinary Sciences

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford, David J. DiLillo, Richard Tavare, Erica Ullman, Shu Mao, Lauren Canova, Olga Sineshchekova, Jennifer Finney, Arpita Pawashe, Supriya Patel, Ryan McKay, Sahar Rizvi, Ermelinda Damko, Danica Chiu, Kristin Vazzana, Priyanka Ram, Katja Mohrs, Amanda D'Orvilliers, Jenny Xiao, Sosina Makonnen, Carlos Hickey, Cody Arnold, Jason Giurleo, Ya Ping Chen, Courtney Thwaites, Drew Dudgeon, Kevin Bray, Ashique Rafique, Tammy Huang, Frank Delfino, Aynur Hermann, Jessica R. Kirshner, Marc W. Retter, Robert Babb, Douglas MacDonald, Gang Chen, William C. Olson, Gavin Thurston, Samuel Davis, John C. Lin, Eric Smith

Summary: By altering the binding affinity for CD3 alone, researchers can generate bispecific antibodies that maintain potent killing of TSA+tumor cells but display differential patterns of cytokine release, pharmacokinetics, and biodistribution, thus improving the therapeutic index of T-cell-engaging bispecific antibodies.

SCIENTIFIC REPORTS (2021)

Article Oncology

Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification

Andrew M. Leader, John A. Grout, Barbara B. Maier, Barzin Y. Nabet, Matthew D. Park, Alexandra Tabachnikova, Christie Chang, Laura Walker, Alona Lansky, Jessica Le Berichel, Leanna Troncoso, Nausicaa Malissen, Melanie Davila, Jerome C. Martin, Giuliana Magri, Kevin Tuballes, Zhen Zhao, Francesca Petralia, Robert Samstein, Natalie Roy D'Amore, Gavin Thurston, Alice O. Kamphorst, Andrea Wolf, Raja Flores, Pei Wang, Soren Muller, Ira Mellman, Mary Beth Beasley, Helene Salmon, Adeeb H. Rahman, Thomas U. Marron, Ephraim Kenigsberg, Miriam Merad

Summary: This study identified a cellular module called lung cancer activation module (LCAM(hi)) in early-stage NSCLC lesions, which consists of activated T cells, plasma cells, and macrophages, and is associated with enhanced response to immunotherapy. LCAM presence was found to be independent of overall immune cell content and correlated with TMB, cancer testis antigens, and TP53 mutations, suggesting it may serve as a nonredundant biomarker for immunotherapy response in NSCLC patients.

CANCER CELL (2021)

Article Gastroenterology & Hepatology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C. Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O. Kamphorst, Muhammed Shareef, Namita T. Gupta, Raquel Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Guray Akturk, Mark Buckup, Steven Hamel, Giorgio Ioannou, Clotilde Hennequin, Hajra Jamal, Haley Brown, Antoinette Bonaccorso, Daniel Labow, Umut Sarpel, Talia Rosenbloom, Max W. Sung, Baijun Kou, Siyu Li, Vladimir Jankovic, Nicola James, Sara C. Ham, Hung Kam Cheung, Jennifer S. Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Tauli, Myron E. Schwartz, Miriam Merad

Summary: This study evaluated the clinical activity of neoadjuvant cemiplimab in patients with resectable hepatocellular carcinoma. The results showed that treatment with cemiplimab resulted in significant tumor necrosis and partial response in some patients. Adverse events were common but severe adverse events were rare. These findings contribute to further understanding the clinical benefit of preoperative PD-1 blockade in patients with hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Hematology

Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

Matt Weinstock, Pavania Elavalakanar, Susan Bright, Srikanth R. Ambati, Jurriaan Brouwer-Visser, Stephane Pourpe, Nathalie Fiaschi, Vladimir Jankovic, Gavin Thurston, Raquel P. Deering, Aafia Chaudhry, Robin Joyce, Jon Arnason

Summary: CAR-T cell therapy has limited efficacy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. However, treatment with Odronextamab in these patients has shown durable and manageable responses.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Multidisciplinary Sciences

Efficient engraftment and viral transduction of human hepatocytes in an FRG rat liver humanization model

Marisa Carbonaro, Jeffrey Lee, Evangelos Pefanis, Mathieu Desclaux, Kehui Wang, Alexander Pennington, Hui Huang, Alejo Mujica, Jose Rojas, Roxanne Ally, Daniel Kennedy, Michael Brown, Vitaliy Rogulin, Sven Moller-Tank, Leah Sabin, Brian Zambrowicz, Gavin Thurston, Zhe Li

Summary: Humanized liver rodent models, an important tool in drug development and disease research, have been increasingly used. Researchers have successfully generated a rat model similar to humanized liver mice and developed new methods for studying liver disease and hepatocyte-targeted therapies.

SCIENTIFIC REPORTS (2022)

Article Multidisciplinary Sciences

Common and rare variant associations with clonal haematopoiesis phenotypes

Michael D. Kessler, Amy Damask, Sean O'Keeffe, Nilanjana Banerjee, Dadong Li, Kyoko Watanabe, Anthony Marketta, Michael Van Meter, Stefan Semrau, Julie Horowitz, Jing Tang, Jack A. Kosmicki, Veera M. Rajagopal, Yuxin Zou, Yariv Houvras, Arkopravo Ghosh, Christopher Gillies, Joelle Mbatchou, Ryan R. White, Niek Verweij, Jonas Bovijn, Neelroop N. Parikshak, Michelle G. LeBlanc, Marcus Jones, David J. Glass, Luca A. Lotta, Michael N. Cantor, Gurinder S. Atwal, Adam E. Locke, Manuel A. R. Ferreira, Raquel Deering, Charles Paulding, Alan R. Shuldiner, Gavin Thurston, Adolfo A. Ferrando, Will Salerno, Jeffrey G. Reid, John D. Overton, Jonathan Marchini, Hyun M. Kang, Aris Baras, Goncalo R. Abecasis, Eric Jorgenson

Summary: Clonal haematopoiesis, associated with ageing and adverse health outcomes, involves the expansion of certain blood cell lineages. This study identified novel germline genetic variations influencing predisposition to clonal haematopoiesis using exome sequence data from over 600,000 individuals. The study also found associations between clonal haematopoiesis and severe COVID-19 outcomes, cardiovascular disease, and malignancy.

NATURE (2022)

Article Cell Biology

CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models

Joyce Wei, Welby Montalvo-Ortiz, Lola Yu, Amanda Krasco, Kara Olson, Sahar Rizvi, Nathalie Fiaschi, Sandra Coetzee, Fang Wang, Erica Ullman, Hassan Shakil Ahmed, Evan Herlihy, Ken Lee, Lauren Havel, Terra Potocky, Sarah Ebstein, Davor Frleta, Aditi Khatri, Stephen Godin, Sara Hamon, Jurriaan Brouwer-Visser, Travis Gorenc, Doug MacDonald, Aynur Hermann, Aafia Chaudhry, Andres Sirulnik, William Olson, John Lin, Gavin Thurston, Israel Lowy, Andrew J. Murphy, Eric Smith, Vladimir Jankovic, Matthew A. Sleeman, Dimitris Skokos

Summary: The combination of odronextamab and REGN5837 could provide a chemotherapy-free approach for the treatment of DLBCL, as REGN5837 enhances the antitumor activity of odronextamab by potentiating T cell activation and cytolytic function. Preclinical studies have shown promising results, and the presence of a population of CD28+CD8+ T cells after odronextamab treatment suggests potential targeting by REGN5837.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Oncology

Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054

Richard Tavare, Makenzie Danton, Jason T. Giurleo, Sosina Makonnen, Carlos Hickey, Tomas C. Arnold, Marcus P. Kelly, Fanny Fredriksson, Karina Bruestle, Aynur Hermann, Erica Ullman, Kurt H. Edelmann, Terra Potocky, Drew Dudgeon, Nikunj B. Bhatt, Mikhail Doubrovin, Thomas Barry, Christos A. Kyratsous, Cagan Gurer, Naxin Tu, Hans Gartner, Andrew Murphy, Lynn E. Macdonald, Jon Popke, Akiva Mintz, Adam Griesemer, William C. Olson, Gavin Thurston, Dangshe Ma, Jessica R. Kirshner

Summary: Assessment of immune-cell subsets within the tumor immune microenvironment using immuno-positron emission tomography (PET) is a promising approach. This study developed 89Zr-DFO-REGN5054 to monitor CD8 thorn tumor-infiltrating lymphocytes (TIL) and demonstrated minimal impact on T-cell activity. Preclinical immuno-PET studies and toxicology studies in monkeys showed specific targeting to lymphoid tissues and no overt toxicity.

CANCER IMMUNOLOGY RESEARCH (2022)

Letter Gastroenterology & Hepatology

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma reply

Thomas U. Marron, Myron E. Schwartz, Elizabeth Miller, Pradeep Thanigaimani, Israel Lowy, Gavin Thurston, Miriam Merad

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Oncology

A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma

Nikos Kourtis, Qingqing Wang, Bei Wang, Erin Oswald, Christina Adler, Samvitha Cherravuru, Evangelia Malahias, Lance Zhang, Jacquelynn Golubov, Qiaozhi Wei, Samantha Lemus, Min Ni, Yueming Ding, Yi Wei, Gurinder S. Atwal, Gavin Thurston, Lynn E. Macdonald, Andrew J. Murphy, Ankur Dhanik, Matthew A. Sleeman, Scott S. Tykodi, Dimitris Skokos

Summary: This study maps the chromatin landscape of immune cells in patients with early-stage clear cell renal cell carcinoma (ccRCC) and identifies the association between NF-kappa B and dysfunction in CD8(+) T cells. Importantly, it provides a valuable resource for understanding the functional states and regulatory dynamics of immune cells in ccRCC.

NATURE CANCER (2022)

暂无数据